Empower Cellular Growth with Advanced Scaffolds

Introduction

The field of cell culture and tissue engineering is advancing rapidly, with increasing demand for more efficient, scalable, and reliable methods of growing mammalian cells. Our patented microcarriers, matrices, and scaffolds provide an innovative solution for supporting cell growth and differentiation, offering unmatched versatility for biomanufacturing, regenerative medicine, and drug development. With a focus on efficiency, biocompatibility, and performance, this technology helps overcome the current limitations of conventional cell culture methods, empowering industries to take their cellular research and production to the next level.

Barriers in Cell Culture and Tissue Engineering

Scaling up the production of mammalian cells for research, therapy, or pharmaceutical applications has historically presented numerous challenges. Traditional cell culture methods often require significant space, time, and resources, while limiting the ability to control the growth environment. In tissue engineering, building scaffolds that can support cellular differentiation and tissue formation is essential for advancing regenerative medicine, yet conventional options often lack the ability to mimic natural cellular environments.

Both fields are seeking more efficient and reliable methods to improve cell yields and promote more consistent cellular behavior, while simultaneously scaling the production of high-quality cells for therapeutic applications.

Why Choose Advanced Cellular Growth Scaffolds?

Our patented technology offers an elegant solution through microcarriers, matrices, and scaffolds that are designed for optimal mammalian cell culture. These materials provide a superior environment for cell attachment, growth, and differentiation, allowing for more efficient cell expansion and tissue formation. Whether used in bioreactors for mass production or in tissue engineering for regenerative medicine, these scaffolds enhance the overall process, yielding better results with less resource investment.

The biocompatibility of these scaffolds ensures they are safe for use in medical applications, while their structure mimics the natural extracellular matrix, promoting more realistic cellular growth and behavior. These microcarriers are designed to facilitate large-scale cell culture in a variety of applications, making them ideal for biopharma companies, research labs, and tissue engineers alike.

Key Benefits

Enhanced Cell Growth: Provides optimal conditions for mammalian cell attachment, expansion, and differentiation.
Scalable Production: Ideal for large-scale biomanufacturing, improving efficiency in cell culture processes.
Biocompatible and Versatile: Suitable for use in regenerative medicine, drug development, and tissue engineering.
Advanced Tissue Engineering: Supports realistic tissue formation with scaffolds that mimic natural cellular environments.

Fuel Breakthroughs with Advanced Cellular Growth Scaffolds

Licensing this cutting-edge scaffold technology offers companies a powerful tool to enhance cell culture, improve tissue engineering outcomes, and streamline biomanufacturing. With its combination of biocompatibility, scalability, and performance, this technology unlocks new possibilities for breakthroughs in biotechnology and regenerative medicine.

Please see terms and conditions

Abstract
Claims

Microcarriers, matrices and scaffolds for growing mammalian cells are provided which include copolymer particles and matrices comprising of polysaccharide-polyamine copolymers. The copolymeric particles and matrices have a pore size of at least 50 microns and permit the mammalian cells to grow both on an exterior surface of the particles and matrices and within an interior of the particles and matrices. Methods for making such microcarriers, matrices and scaffolds, and compositions are also provided. Methods for growing mammalian cells utilizing such microcarriers, matrices and scaffolds and compositions are also provided.

What is claimed is:

1. Polysaccharide-polyamine copolymer or glycoprotein-polyamine copolymers having an amino functionality which will provide a cationic copolymeric material having a three-dimensional structure with cationic sites when protonated, the polysaccharide-polyamine copolymer comprising:

a selectively oxidized polysaccharide or selectively oxidized glycoproteins, both the selectively oxidized polysaccharide and the selectively oxidized glycoproteins having a 2,3-dialdehyde moiety; and

amino polymers which provide an amino functionality, the amino polymers cross-linking the oxidized polysaccharides to provide a particulate polysaccharide-polyamine copolymer or glycoprotein-polyamine copolymers having an amino functionality, the polysaccharide-polyamine copolymer or the glycoprotein-polyamine copolymers having a pore size configured to support cells on an interior surface,

wherein the amino polymers have a nitrogen content of at least 0.5% and no more than 30 wt. %, based on the weight of the amino polymers, and wherein the amino polymers have a molecular weight in the range of from about 15,000 to about 900,000.

2. A method of producing the polysaccharide-polyamine copolymers or glycoprotein-polyamine copolymers according to claim 1, the method comprising the steps of:

providing an oxidized polysaccharide or oxidized glycoprotein having aldehyde moieties;

reacting the oxidized polysaccharide or oxidized glycoprotein with an amino polymer to form a polymer containing imine derivatives; and

converting the imine derivatives on the polymer to amines to form the polysaccharide-polyamine copolymers or glycoprotein-polyamine copolymers, the polysaccharide-polyamine copolymers or glycoprotein-polyamine copolymers having an amino functionality which will provide a cationic copolymeric material having a three-dimensional structure with cationic sites when protonated.

3. The method of claim 2 wherein the polysaccharide-polyamine copolymers or glycoprotein-polyamine copolymers are di-block copolymers.

4. The method of any one of claim 2 wherein the aldehyde moieties are generated by selectively oxidizing hydroxyl groups on C2 and C3 of glucose units and the oxidation does not produce more carboxyl groups than aldehyde groups or cause cleavage of a polysaccharide chain.

5. The method of claim 2 further comprising the step of drying the polysaccharide-polyamine copolymers or glycoprotein-polyamine copolymers to form polysaccharide-polyamine copolymer particles or glycoprotein-polyamine copolymer particles.

6. The method of claim 2 wherein the selectively oxidized polysaccharide is selected from the group consisting of selectively oxidized cellulose, selectively oxidized starch, selectively oxidized amylose, selectively oxidized chitosan, selectively oxidized dextran, selectively oxidized glycogen, selectively oxidized chitin, polysaccharide side chain of mucin, and mixtures thereof, the polysaccharide having been oxidized in an amount effective to provide a 2,3-dialdehyde moiety which is reactive with the amino polymers.

7. The method of claim 2 wherein the amino polymers are selected from the group consisting of polyethyleneimine, poly(allylamine) and polypropylenimine tetramine, protein, polypeptides, and mixtures thereof.

8. The method of claim 2 wherein the polysaccharide-polyamine copolymer or cationic copolymer has particulates having an average pore sizes of greater than about 50 μm.

9. The polysaccharide-polyamine copolymer or the glycoprotein-polyamine copolymers of claim 1, wherein the selectively oxidized polysaccharide is selected from the group consisting of selectively oxidized cellulose, selectively oxidized starch, selectively oxidized amylose, selectively oxidized chitosan, selectively oxidized dextran, selectively oxidized glycogen, selectively oxidized chitin, polysaccharide side chain of mucin, and mixtures thereof, the polysaccharide having been oxidized in an amount effective to provide the 2,3-dialdehyde moiety which is reactive with the amino polymers.

10. The polysaccharide-polyamine copolymer or the glycoprotein-polyamine copolymers of claim 1, wherein the selectively oxidized polysaccharide have β-1,4-glycosidic bonds or β-1,6-glycosidic bonds.

11. The polysaccharide-polyamine copolymer or the glycoprotein-polyamine copolymers of claim 1, wherein the selectively oxidized polysaccharide have β-1,4-glycosidic bonds.

12. The polysaccharide-polyamine copolymer or the glycoprotein-polyamine copolymers of claim 1, wherein the selectively oxidized polysaccharide is selected from the group consisting of selectively oxidized cellulose, selectively oxidized chitosan, selectively oxidized chitin, selectively oxidized amylose and mixtures thereof.

13. The polysaccharide-polyamine copolymer or the glycoprotein-polyamine copolymers of claim 1, wherein the amino polymers which provide a cationic amino functionality are selected from the group consisting of polyethyleneimine, poly(allylamine) and polypropylenimine tetramine, protein, polypeptides, and mixtures thereof.

14. The polysaccharide-polyamine copolymer or the glycoprotein-polyamine copolymers of claim 1, wherein the amino polymers are in a linear, branched or dendritic form.

15. The polysaccharide-polyamine copolymers or the amino glycoprotein copolymers of claim 1, wherein the particulates of the polysaccharide-polyamine copolymer or the amino glycoprotein copolymers and cationic copolymeric material have sizes in the range of from about 100 μm to about 10 mm.

16. The polysaccharide-polyamine copolymer or the amino glycoprotein copolymers of claim 1, wherein the particulate polysaccharide-polyamine copolymer or cationic copolymeric material has particulates having an average pore sizes of greater than about 50 μm.

17. Polysaccharide-polyamine copolymer or glycoprotein-polyamine copolymers having an amino functionality which will provide a cationic copolymeric material having a three-dimensional structure with cationic sites when protonated, the polysaccharide-polyamine copolymer comprising:

wherein the particulate polysaccharide-polyamine copolymer or cationic copolymeric material has particulates having an average pore sizes of greater than about 50 μm.

Title

Microcarriers, matrices and scaffolds for culturing mammalian cells and methods of manufacture

Inventor(s)

James W. Mitchell, Dazhi Yang

Assignee(s)

Howard University

Patent #

10723809

Patent Date

July 28, 2020